Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment

Area of Science:

• Oncology
• Cancer Biology
• Genetics

Background:

• Melanoma treatments like targeted therapies (MAPK pathway) and immunotherapies offer clinical benefits but often face patient resistance and disease relapse.
• Melanoma exhibits mutations in homologous recombination (HR) and DNA damage response (DDR) genes, alongside high replicative stress, leading to increased endogenous DNA damage and DDR activation.

Purpose of the Study:

• To review the therapeutic potential of exploiting DNA damage response (DDR) pathways in melanoma.
• To focus on specific DDR inhibitors (PARP, ATM, CHK1, WEE1, ATR) and their application in melanoma treatment.

Main Methods:

• Review of current experimental evidence on DDR in melanoma.
• Analysis of preclinical data for DDR inhibitors as single agents and in combination therapies.
• Examination of synthetic lethal interactions involving DDR pathways.

Main Results:

• Preclinical data demonstrate the growing efficacy of DDR inhibitors in melanoma, both as monotherapies and in combination with chemo-targeted-immunotherapy.
• Synthetic lethal interactions are being explored to enhance the effectiveness of DDR inhibitors.

Conclusions:

• Exploiting DDR pathways presents a promising therapeutic avenue for melanoma treatment.
• DDR inhibitors, supported by preclinical and ongoing clinical data, may significantly impact the future of melanoma therapy, especially for resistant cases.